Dated: August 5, 1996.

Wilma G. Johnson,

Acting Associate Director for Policy Planning and Evaluation, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96–20322 Filed 8–8–96; 8:45 am]

BILLING CODE 4163–18–P]

Notice of Meeting

Office of the Director, Centers for Disease Control and Prevention (CDC), announces the following meeting.

Name: Guide to Community Preventive Services (GCPS) Task Force Meeting.

Times and Dates: 8:30 a.m.–5 p.m., August 26, 1996; 8:30 a.m.–5 p.m., August 27, 1996.

Place: CDC, Building 2, Classroom 1, 1600 Clifton Road, NE, Atlanta, Georgia 30333.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 60 people.

Purpose: The mission of the Task Force is to develop and publish a Guide to Community Preventive Services, which is based on the best available scientific evidence and current expertise regarding essential public health services and what works in the delivery of those services. The primary purpose of this first meeting is to develop a shared vision for the Guide, agree on the methods to be used in its development, and to select the first topics to be included in the Guide.

Matters to be Discussed: Agenda items include: key issues for the Guide to Community Preventive Services; defining the Target Audiences and Developing a Vision for the Anticipated Uses; Nature of the Content and Format of the Guide; Applicable lessons learned from the Guidelines Project of the Council on Linkages Between Academia and Public Health Practice; Methods and Approaches to Developing the Guide to Community Preventive Services; and Proposed Approach to the Development of the GCPS.

Agenda items are subject to change as priorities dictate.

Contact Person for Additional Information: Marguerite Pappaioanou, the GCPS Project Director at CDC and Executive Secretary to the Task Force, Office of the Director, CDC, 1600 Clifton Road, NE, M/S D–27, Atlanta, Georgia 30333, telephone 404/639–7069.

Persons interested in reserving a space for this meeting should call 404/639–7100 by close of business on August 21, 1996.

Dated: August 5, 1996.

Nancy C. Hirsch,

Acting Director, Management Analysis and Services Office Centers for Disease Control and Prevention (CDC).

[FR Doc. 96–20320 Filed 8–8–96; 8:45 am]

BILLING CODE 4163–18–M

National Vaccine Advisory Committee (NVAC) Subcommittee on Immunization Coverage: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following Federal advisory committee meeting.

Name: NVAC Subcommittee on Immunization Coverage.

Times and Dates: 1:30 p.m.–5:30 p.m., August 26, 1996; 8:30 a.m.–3:30 p.m., August 27, 1996.

Place: American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois 60007.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 100 people.

Purpose: The Subcommittee will advise and make recommendations to the full Committee on matters related to the improvement of immunization coverage rates.

Matters to be Discussed: Agenda items include presentations from CDC researchers on immunization diagnostic projects; and from the state and city immunization programs on their program operations and challenges they face. The Subcommittee will host two panels of immunization providers discussing assessments they are performing in their practices and other innovative methods of increasing immunization coverage rates.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Alison B. Johnson, Program Analyst, National Immunization Program, CDC, 1600 Clifton Road, NE, M/S E52, Atlanta, Georgia 30333, telephone 404/639–8222.

Dated: August 5, 1996.

Nancy C. Hirsch,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96–20321 Filed 8–8–96; 8:45 am]

BILLING CODE 4163–18–M

Food and Drug Administration

[Docket No. 96N–0165]

Rhone Merieux, Inc.; Withdrawal of Approval of NADA

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of a new animal drug application (NADA) held by Rhone Merieux, Inc. The NADA provides for the use of Gallimycin® (erythromycin) Poultry Formula in poultry drinking water. The sponsor requested the withdrawal of approval because the animal drug product is no longer manufactured or marketed.

EFFECTIVE DATE: August 19, 1996.

FOR FURTHER INFORMATION CONTACT: Dianne T. McRae, Center for Veterinary Medicine (HFV–102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1623.

SUPPLEMENTARY INFORMATION: Rhone Merieux, Inc., P.O. Box 459, 2116 Eighth Avenue South, Fort Dodge, IA 50501, is the sponsor of NADA 102–656, which provides for the use of Gallimycin® (erythromycin) Poultry Formula in poultry drinking water. By letter of April 17, 1996, Rhone Merieux, Inc., requested withdrawal of approval of the NADA because the animal drug product is no longer manufactured or marketed.

Therefore, under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Veterinary Medicine (21 CFR 5.84), and in accordance with § 514.115 *Withdrawal of approval of applications* (21 CFR 514.115), notice is given that approval of NADA 102–656 and all supplements and amendments thereto is hereby withdrawn, effective August 19, 1996.

Dated: July 17, 1996.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

[FR Doc. 96–20341 Filed 8–8–96; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 96E–0101]

Determination of Regulatory Review Period for Purposes of Patent Extension; CEDAX®

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) has determined the regulatory review period for CEDAX® and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.

ADDRESSES: Written comments and petitions should be directed to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Brian J. Malkin, Office of Health Affairs (HFY–20), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–1382.

SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98–417) and the Generic Animal Drug and Patent